๐
Kauliv
teriparatide
Osteoporosis;Osteoporosis, Postmenopausal
โ
Authorised
Biosimilar
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Kauliv is indicated in adults. Treatment of osteoporosis in postmenopausal women and in men at increased risk of fracture (see section 5.1). In postmenopausal women, a significant reduction in the incidence of vertebral and non-vertebral fractures but not hip fractures has been demonstrated. Treatment of osteoporosis associated with sustained systemic glucocorticoid therapy in women and men at increased risk for fracture (see section 5.1).
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/kauliv